KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

CPX-351 selectively benefits patients with AML and myelodysplasia-related mutations in the pivotal randomized trial.

Blood Adv · 2026-Apr-28 · PMID 41628350

Panel C提取完成待 EXE 对齐验证

OS

Figure 2. OS by genetic classification and treatment arm (CPX-351 vs 7+3). (A) OS in AML-MR by treatment. (B) OS in TP53 -AML by treatment arm. (C) OS in other-AML by treatment arm. (D) OS in DDX41 -AML by treatment arm. Time is measured from random assignment.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分1.00
质量通过是
预期曲线2
实际曲线2
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0complete待验证22026-07-18T19:10:43+00:00